Cargando…

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

OBJECTIVES: To report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP). METHODS: This phase III, randomised trial was placebo-controlled and doubl...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Heijde, Désirée, Baraliakos, Xenofon, Hermann, Kay-Geert A, Landewé, Robert B M, Machado, Pedro M, Maksymowych, Walter P, Davies, Owen R, de Peyrecave, Natasha, Hoepken, Bengt, Bauer, Lars, Nurminen, Tommi, Braun, Juergen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909752/ https://www.ncbi.nlm.nih.gov/pubmed/29343510 http://dx.doi.org/10.1136/annrheumdis-2017-212377

Ejemplares similares

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis
por: Braun, Jürgen, et al.
Publicado: (2017)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy
por: Robinson, Philip C., et al.
Publicado: (2019)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
por: Robinson, Philip C., et al.
Publicado: (2022)

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
por: Maksymowych, Walter P., et al.
Publicado: (2023)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression
por: Stal, Rosalinde, et al.
Publicado: (2020)

Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2023)

Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years
por: Stal, Rosalinde, et al.
Publicado: (2022)

Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2022)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis
por: Marques, Mary Lucy, et al.
Publicado: (2022)

Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals
por: Korkosz, Mariusz, et al.
Publicado: (2018)

Non-radiographic versus radiographic axSpA: what’s in a name?
por: Michelena, Xabier, et al.
Publicado: (2020)

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial
por: Stal, Rosalinde, et al.
Publicado: (2023)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
por: Maksymowych, Walter P., et al.
Publicado: (2021)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS
por: Macfarlane, Gary J, et al.
Publicado: (2020)

Association of anxiety, depression and resilience with overall health and functioning in axial spondyloarthritis (axSpA): a cross-sectional study
por: Chung, Deborah Xin Yi, et al.
Publicado: (2023)

Beantwortung epidemiologisch-rheumatologischer Fragestellungen durch Kooperation mit der bevölkerungsbasierten SHIP-Kohorte – Erkenntnisse für die Diagnostik der axialen Spondyloarthritis (axSpA)
por: Braun, J., et al.
Publicado: (2021)

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort
por: Hebeisen, Monika, et al.
Publicado: (2020)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?
por: Siebuhr, Anne Sofie, et al.
Publicado: (2018)

Quality and acceptability of patient-reported outcome measures used to assess fatigue in axial spondyloarthritis (axSpA): a systematic review (protocol)
por: Pearson, Nathan A., et al.
Publicado: (2018)

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Sepriano, Alexandre, et al.
Publicado: (2017)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Regel, Andrea, et al.
Publicado: (2017)

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
por: Maksymowych, Walter P, et al.
Publicado: (2022)

The Role of Imaging in Diagnosing Axial Spondyloarthritis
por: Khmelinskii, Nikita, et al.
Publicado: (2018)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_897nro0dnfsr5f6c0a13n93f2f